COVID-19 Vaccination Rates in a Global HIV Cohort. (18th November 2021)

• Record Type: Journal Article
• Authors: Fulda, Evelynne S; Fitch, Kathleen V; Overton, Edgar T; Zanni, Markella V; Aberg, Judith A; Currier, Judith S; Lu, Michael T; Malvestutto, Carlos; Fichtenbaum, Carl J; Martinez, Esteban; Umbleja, Triin; Douglas, Pamela S; Ribaudo, Heather J; Grinspoon, Steven K
• Is Part Of: Journal of infectious diseases. Volume 225:Number 4(2022)
• Page Start: 603
• Page End: 607
• Publication Date: 2021-11-18
• Subjects: human immunodeficiency virus -- COVID-19 -- vaccination -- Global Burden of Disease region; Communicable diseases -- Periodicals; Diseases -- Causes and theories of causation -- Periodicals; Medicine -- Periodicals; Communicable Diseases -- Periodicals; Electronic journals; 616.9
• DOI: 10.1093/infdis/jiab575
• Languages: English
• ISSNs: 0022-1899

Abstract

Abstract: Little is known regarding coronavirus disease 2019 (COVID-19) vaccination rates in people with HIV (PWH), a vulnerable population with significant morbidity from COVID-19. We assessed COVID-19 vaccination rates among 6952 PWH in the Randomized Trial to Prevent Vascular Events in HIV (REPRIEVE) compared to region- and country-specific vaccination data. The global probability of COVID-19 vaccination through end of July 2021 was 55% among REPRIEVE participants with rates varying substantially by Global Burden of Disease (GBD) superregion. Among PWH, factors associated with COVID-19 vaccination included residence in high-income regions, age, white race, male sex, body mass index, and higher cardiovascular risk. Clinical Trials Registration. NCT02344290.